Biocon wins 10-year Brazil supply deal for breast cancer drug

Business Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹391.50

prior close

₹392.15

announcement price

After-mkt

timing

Nifty Midcap 150market+0.1%+0.1% vs market

Pharmaceuticals peers, median of 176sector+0.1%+0.1% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.7

10m

+1.0

15m

+0.7

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+0.1+0.1+0.1+0.1

Next day

+0.9-0.3+1.2-0.3+1.2

+0.0-0.7+0.7+0.0+0.0

-0.2-0.9+0.7-0.6+0.3

-2.4-3.1+0.6-2.0-0.5

-4.4-3.0-1.4-2.0-2.4

-0.9-0.7-0.2-0.8-0.1

15d

-5.4-5.2-0.2-1.8-3.6

-10.6-7.6-3.0-4.4-6.2

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 176Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon, with Brazilian partners Bahiafarma and Bionovis, secured 100% allocation under Brazil's 10-year Productive Development Partnership (PDP) program for Pertuzumab, a HER2-positive breast cancer therapy. The consortium gets exclusive access to Brazil's public healthcare market, about 70% of the country's Pertuzumab demand. Biocon will earn milestone payments and a share of revenues over 10 years, with phased local manufacturing in Brazil. Pertuzumab is currently not produced locally and is a significant cost for Brazil's Unified Health System (SUS).

Likely market impact

Long-term revenue visibility and entry into Brazil's public oncology market; positive for growth outlook, though value not disclosed.